Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230000, China.
The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China.
Invest New Drugs. 2021 Oct;39(5):1436-1438. doi: 10.1007/s10637-021-01122-5. Epub 2021 Apr 29.
Gastric cancer (GC) has the third highest rate of cancer incidence and mortality worldwide. First-line immune checkpoint inhibitor (ICI) therapy for advanced GC led to landmark breakthroughs, but which GC patients are most likely to benefit from ICI therapy needs to be investigated in depth and identified via valuable biomarkers. In this letter, we describe superior outcomes in Asian patients than in North American and European patients treated with ICI therapy, and we speculate that positive H. pylori status may be a beneficial prognostic factor for ICI therapy in patients with GC. Many studies have revealed that H. pylori-activated immune responses improve prognosis in patients with GC via increased PD-L1 expression and CD3 T cells. We propose that H. pylori status should be emphasized in ongoing or forthcoming ICI therapy trials to maximize the benefits of treatment for patients with advanced GC. Further research is required to better understand the mechanisms of inflammation and cancer progression.
胃癌（GC）是全球发病率和死亡率第三高的癌症。用于治疗晚期 GC 的一线免疫检查点抑制剂（ICI）治疗带来了里程碑式的突破，但哪些 GC 患者最有可能从 ICI 治疗中获益仍需要深入研究，并通过有价值的生物标志物来确定。在这封信中，我们描述了亚洲患者接受 ICI 治疗的结果优于北美和欧洲患者，并推测 H. pylori 阳性状态可能是 GC 患者接受 ICI 治疗的有益预后因素。许多研究表明，H. pylori 激活的免疫反应通过增加 PD-L1 表达和 CD3 T 细胞改善 GC 患者的预后。我们建议在正在进行或即将进行的 ICI 治疗试验中强调 H. pylori 状态，以最大限度地提高晚期 GC 患者治疗的获益。需要进一步研究以更好地了解炎症和癌症进展的机制。
